Pharmafile Logo

MENA

- PMLiVE

Europe responding to gene therapy challenge, but picture remains fragmented

Germany, Italy and England using outcomes-based deals

- PMLiVE

Orphan drugs market to soar to $224bn by 2024

Cell and gene therapies to fuel growth

- PMLiVE

Vertex chief Jeffrey Leiden to weigh in on Orkambi inquiry

Will be joined by chief commercial officer Stuart Arbuckle

Live webinar: Navigating new frontiers: Ways to find space in the future RA market

In partnership with pharmaphorumThursday 21st March 201915:00 GMT / 16:00 CETRegister now to secure your place »The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors,...

Research Partnership

- PMLiVE

Rare Diseases Day

More than other conditions, rare diseases require a human touch, but technology can provide a vital helping hand

Statistics and Infographics for Rare Disease Day

Rare Disease Day 2019

Today is #RareDiseaseDay and is an opportunity to highlight some truly unbelievable/frightening statistics around rare diseases.

Cuttsy + Cuttsy

- PMLiVE

‘Inflexible’ NICE blocking access to rare disease drugs

Spinraza most high profile example of access problem

- PMLiVE

Industry concerned about ‘rushed’ Brexit withdrawal legislation

The Patents Amendment could weaken the UK’s IP framework, warns biopharma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links